TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04398199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: The prescribed dose will be 70 Gy in 25 fractions. Participants will radiation therapy once a day for 25 days, Monday through Friday (around 5 weeks).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Boost
Description: Undergo simultaneous integrated boost (SIB) to treat both planned target volumes with daily image guidance. This approach allows daily confirmation of target localization and simultaneous delivery of lower dose per fraction to low risk areas while maintaining a high dose per fraction to the highest risk areas.
Study: NCT01562704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol (drug)
Description: The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation
Study: NCT03195075

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasonography guided biliary drainage
Description: Endoscopic ultrasonography guided biliary drainage includes rendezvous techniques, endoscopic ultrasonography guided choledochoduodenostomy, and endoscopic ultrasonography-guided hepatogastrostomy using self-expandable metal stent will be done for group 1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous trans-hepatic biliary drainage
Description: Percutaneous trans-hepatic biliary drainage in interventional radiology department using self-expandable metal stent will be done for group 2
Study: NCT03000842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagal nerve stimulation on
Description: electrical current on positioned in the ear to estimate vagal branch of auricular nerve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagal nerve stimulation on
Description: electrical current on positioned in the ear to estimate vagal branch of auricular nerve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagal nerve stimulation off
Description: an electrical current off positioned in the ear to estimate vagal branch of auricular nerve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagal nerve stimulation off
Description: an electrical current off positioned in the ear to estimate vagal branch of auricular nerve
Study: NCT03999034

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaire completion
Description: Every patient (140) and healthy control (400) will fill in all the tests and questionnaires, except FSS, in a random order during a single appointment. The FSS will be fill in by patients only. All 400 healthy controls will be divided in 20 groups of 20 people, according to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not). 60 of them will pass the XO test at the beginning and again at the end of the consult to investigate the test-retest effect.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaire completion
Description: Every patient (140) and healthy control (400) will fill in all the tests and questionnaires, except FSS, in a random order during a single appointment. The FSS will be fill in by patients only. All 400 healthy controls will be divided in 20 groups of 20 people, according to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not). 60 of them will pass the XO test at the beginning and again at the end of the consult to investigate the test-retest effect.
Study: NCT02288624

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Processed orange juice
Description: 3 different formulation of edible orange drinks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Processed orange juice
Description: 3 different formulation of edible orange drinks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Processed orange juice
Description: 3 different formulation of edible orange drinks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Processed orange juice
Description: 3 different formulation of edible orange drinks
Study: NCT00546481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin
Description: As prescribed, iv, 3 times weekly
Study: NCT03576235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG102P
Description: Daily dose of 1.5g
Study: NCT02010944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron/solifenacin succinate
Description: oral
Study: NCT03576235

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of placebo
Study: NCT03703388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arctigenin
Description: Arctigenin capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arctigenin
Description: Arctigenin capsule
Study: NCT02010944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron/solifenacin succinate
Description: oral
Study: NCT03277534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: sensory electrical stimulation was applied prior to upper limb functional training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electrical stimulation
Description: electrodes were placed on the same location as the Electrical stimulation condition, but no electric current was applied
Study: NCT00265200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 3.0-4.0 mg by IV (in the vein), once a month for 6 months
Study: NCT00367003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: The deep brain stimulation system (consisting of a lead, extension wire, and implanted pulse generator) will be surgically implanted to stimulate the targeted area of the brain. Stimulation will be turned off for 4 weeks following implantation, then participants will use brain stimulation for 6 months. Participants will also take part in Behavioral Activation therapy during the 6 months of active stimulation. Participants will be followed for 10 years, or until the DBS device has been FDA approved, with adjustments made to the stimulator and medications as necessary.
Study: NCT03703388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arctigenin
Description: Arctigenin capsule
Study: NCT04907630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenatal Education
Description: educational intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenatal Education
Description: educational intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenatal Education
Description: educational intervention
Study: NCT01332045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous saphenous nerve block
Description: Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline boluses in nerve catheter
Description: A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
Study: NCT02437006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: cycle ergometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: cycle ergometry
Study: NCT01346254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: 50mg tablets once daily 20 min before breakfast for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30mg tablets once daily 20 min before breakfast for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-Style Modification
Description: All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Life-Style Modification
Description: All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-Style Modification
Description: All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.
Study: NCT00508924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparin
Study: NCT02021006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrofurantoin
Description: antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No prophylaxis
Description: children will be followed, but no antibiotic prophylaxis will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)
Study: NCT02728024

Intervention type: OTHER
Intervention: Missing items, Errors in Completion, Difficulties
Study: NCT02021006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole
Description: antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefixime
Description: antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)
Study: NCT02474238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The sequential technique
Description: By using 'the double frequency YAG laser' to make the initial bore and 'the Nd:YAG laser' to complete the perforation on iris.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The pure Nd:YAG laser technique
Description: By using 'the pure Nd:YAG laser' to make a complete perforation on iris.
Study: NCT00947453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: montelukast 10 mg once daily for 8 weeks
Study: NCT03655717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol at physician determined doses of 10-80mg designed to produce intoxication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol at physician determined doses of 10-80mg designed to produce intoxication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Oral Ethanol, dosed to obtain a breath alcohol concentration (BrAC) of approximately 0.05 BrAC (equal to 1-2 standard drinks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo dronabinol
Description: Identical in appearance to active dronabinol (overencapsulation of both active and placebo dronabinol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo dronabinol
Description: Identical in appearance to active dronabinol (overencapsulation of both active and placebo dronabinol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ethanol
Description: Placebo ethanol will consist of diet soda used in the active ethanol condition with 0.25ml ethanol floated on top to provide the odor of ethanol and blind the study drug.
Study: NCT04044092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative physical therapy
Description: Moist hot packs, TENS, Cervical Traction, Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELDOA stretching exercise
Description: Experimental group was given ELDOA stretching exercise protocol along with the moist hot packs, TENS, Cervical Traction, and Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
Study: NCT02997917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Study: NCT02043405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss and exercise training intervention
Description: Combined weight loss and exercise training intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss Only Intervention
Description: Weight loss Only Intervention
Study: NCT01561560

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Description: CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Description: CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
Study: NCT02997917

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT00447733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated mental health and substance use treatment
Description: Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Non-standardized psychiatric outpatient treatment
Study: NCT01087762

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Description: 200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CZP 200 mg Q2W
Description: 200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CZP 200 mg Q2W
Description: 200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q4W
Description: 400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CZP 400 mg Q4W
Description: 400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CZP 400 mg Q4W
Description: 400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo to CZP injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo to CZP injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to CZP injection.
Study: NCT04815330

Intervention type: OTHER
Intervention: increment sweep gas flow
Description: If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.

Intervention type: OTHER
Intervention: non-invasive ventilation
Description: In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved.
Study: NCT01138826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine - reference
Description: 10 mg tablet, single dose, with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine ODT - test
Description: 10 mg orally disintegrating tablet (ODT), single dose, with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine ODT - test
Description: 10 mg orally disintegrating tablet (ODT), single dose, without water
Study: NCT03939988

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Immediately after the installation of the separators, the subjects will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo photobiomodulation
Description: In the placebo group, the same procedures will be made, but the laser will be turned off.
Study: NCT03077529

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galacto-oligosacchride
Description: During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
Study: NCT04233086

Intervention type: OTHER
Intervention: No intervention, observational only
Description: No intervention, observational only
Study: NCT00594646

Intervention type: DRUG
Group type: OTHER
Intervention: TRUVADA + Raltegravir
Description: TRUVADA (tenofovir disoproxil fumarate (DF) 300mg + emtricitabine 200mg) + RALTEGRAVIR 400mg
Study: NCT03544398

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: robot assisted gait training
Description: we use two types of robot assisted gait training and we will compare two groups.
Study: NCT02320383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GA101 (Obinutuzumab)
Description: Induction~Cycle 1: d1 - 100 mg, (d1 or) d2 - 900 mg, d8+15 - 1000 mg i.v., q28d~Cycle 2 - 6: d1 - 1000 mg i.v., q28d~Maintenance~GA101 iv 1000 mg (flat dose): every 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Induction~Cycle 1: d3+4 (or d2+3) - 70 mg/m² i.v., q28d~Cycle 2 - 6: d2+3 - 70 mg/m i.v., q28d
Study: NCT03544398

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: robot assisted gait training
Description: we use two types of robot assisted gait training and we will compare two groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: robot assisted gait training
Description: we use two types of robot assisted gait training and we will compare two groups.
Study: NCT03262727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration of specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Description: Oral Contraceptive
Study: NCT04910659

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: P6, LI4 and LI 11 stimulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: P6, LI4 and LI 11 stimulation
Study: NCT03143478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M-MARK
Description: M-MARK will be used by therapists for assessment of the upper limb, and stroke participants will be asked to use M-MARK whilst performing individually tailored and prescribed exercises for a minimum of 5 days/week.~A set of tailored arm exercises using M-MARK (including targets for repetitive and functional activities) will be prescribed which the participant will be asked to practice independently at home for four weeks.~During the four weeks, the patient (with support from their carer as required) will be encouraged to don the M-Mark garment and log-on to the M-Mark computer tablet each day to carry out their programme of exercises. They will be asked to use M-Mark to repeat as many exercise sessions per day as prescribed to them by their research therapist.
Study: NCT00583609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG3350
Description: PEG3350